Cargando…

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor

OBJECTIVE: We compared the effectiveness of abatacept (ABA) versus a subsequent anti-tumour necrosis factor inhibitor (anti-TNF) in rheumatoid arthritis (RA) patients with prior anti-TNF use. METHODS: We identified RA patients from a large observational US cohort (2/1/2000–8/7/2011) who had disconti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrold, Leslie R, Reed, George W, Kremer, Joel M, Curtis, Jeffrey R, Solomon, Daniel H, Hochberg, Marc C, Greenberg, Jeffrey D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316858/ https://www.ncbi.nlm.nih.gov/pubmed/24297378 http://dx.doi.org/10.1136/annrheumdis-2013-203936

Ejemplares similares

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2015)

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
por: Finckh, A, et al.
Publicado: (2010)

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2019)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
por: Kirkham, Bruce W, et al.
Publicado: (2014)

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort
por: Fisher, Anat, et al.
Publicado: (2014)

Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990)

Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
por: Wijbrandts, C A, et al.
Publicado: (2008)

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
por: Hamdi, Haïfa, et al.
Publicado: (2006)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis
por: Rivarola, C, et al.
Publicado: (2008)

Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study
por: Curtis, Jeffrey R., et al.
Publicado: (2015)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
por: Potter, C, et al.
Publicado: (2009)

Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody
por: Pichler, Judith, et al.
Publicado: (2020)

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
por: Feldmann, Marc, et al.
Publicado: (2020)

Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases
por: Lopetuso, Loris Riccardo, et al.
Publicado: (2023)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
por: Rahman, Mahboob U, et al.
Publicado: (2011)

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment
por: Tan, Rachael J L, et al.
Publicado: (2010)

Tumour necrosis factor-α in nasal allergy
por: Hisamatsu, K., et al.
Publicado: (1995)

Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1995)

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2015)

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
por: Cavazzana, I, et al.
Publicado: (2005)

Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy
por: Russo, R, et al.
Publicado: (2011)

Anti‐inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization
por: Assas, B. M., et al.
Publicado: (2016)

Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease
por: Li, Kangrong, et al.
Publicado: (2023)

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
por: Harrison, M J, et al.
Publicado: (2008)

Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis
por: Perry, M G, et al.
Publicado: (2009)

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
por: Emery, P, et al.
Publicado: (2008)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
por: Ching, L. M., et al.
Publicado: (1995)

Carnitine and congeners as regulators of tumour necrosis factor
por: De Simone, Claudio, et al.
Publicado: (1993)

Tumour necrosis factor signalling in health and disease
por: Holbrook, Jonathan, et al.
Publicado: (2019)

Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis
por: Tymms, Kathleen, et al.
Publicado: (2021)

Tumour necrosis factor production and natural killer cell activity in peripheral blood during treatment with recombinant tumour necrosis factor.
por: MÃ¤nnel, D. N., et al.
Publicado: (1989)

Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.
por: Fujimoto, S., et al.
Publicado: (1992)

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
por: Galloway, James B, et al.
Publicado: (2013)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium
por: Catrina, AI, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_9qm81mlqujuf1675mt7opgf1nr